MediciNova, Inc. - Product Pipeline Review - 2014

Date: May 30, 2014
Pages: 47
Price:
US$ 1,500.00 US$ 1,125.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M6D639FCFF2EN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘MediciNova, Inc. - Product Pipeline Review - 2014’, provides an overview of the MediciNova, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of MediciNova, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of MediciNova, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of MediciNova, Inc.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the MediciNova, Inc.’s pipeline products
Reasons to buy
  • Evaluate MediciNova, Inc.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of MediciNova, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the MediciNova, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of MediciNova, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of MediciNova, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of MediciNova, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
MediciNova, Inc. Snapshot
MediciNova, Inc. Overview
Key Information
Key Facts
MediciNova, Inc. - Research and Development Overview
Key Therapeutic Areas
MediciNova, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
MediciNova, Inc. - Pipeline Products Glance
MediciNova, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
MediciNova, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
MediciNova, Inc. - Drug Profiles
bedoradrine sulfate
Product Description
Mechanism of Action
R&D Progress
ibudilast
Product Description
Mechanism of Action
R&D Progress
denibulin hydrochloride
Product Description
Mechanism of Action
R&D Progress
tipelukast
Product Description
Mechanism of Action
R&D Progress
MN-447
Product Description
Mechanism of Action
R&D Progress
MN-462
Product Description
Mechanism of Action
R&D Progress
MediciNova, Inc. - Pipeline Analysis
MediciNova, Inc. - Pipeline Products by Target
MediciNova, Inc. - Pipeline Products by Route of Administration
MediciNova, Inc. - Pipeline Products by Molecule Type
MediciNova, Inc. - Pipeline Products by Mechanism of Action
MediciNova, Inc. - Recent Pipeline Updates
MediciNova, Inc. - Dormant Projects
MediciNova, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AV-333
Coagulin-B
MediciNova, Inc. - Company Statement
MediciNova, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

MediciNova, Inc., Key Information
MediciNova, Inc., Key Facts
MediciNova, Inc. - Pipeline by Indication, 2014
MediciNova, Inc. - Pipeline by Stage of Development, 2014
MediciNova, Inc. - Monotherapy Products in Pipeline, 2014
MediciNova, Inc. - Partnered Products in Pipeline, 2014
MediciNova, Inc. - Partnered Products/ Combination Treatment Modalities, 2014
MediciNova, Inc. - Out-Licensed Products in Pipeline, 2014
MediciNova, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014
MediciNova, Inc. - Phase II, 2014
MediciNova, Inc. - Phase I, 2014
MediciNova, Inc. - Preclinical, 2014
MediciNova, Inc. - Pipeline by Target, 2014
MediciNova, Inc. - Pipeline by Route of Administration, 2014
MediciNova, Inc. - Pipeline by Molecule Type, 2014
MediciNova, Inc. - Pipeline Products by Mechanism of Action, 2014
MediciNova, Inc. - Recent Pipeline Updates, 2014
MediciNova, Inc. - Dormant Developmental Projects,2014
MediciNova, Inc. - Discontinued Pipeline Products, 2014
MediciNova, Inc., Subsidiaries

LIST OF FIGURES

MediciNova, Inc. - Pipeline by Top 10 Indication, 2014
MediciNova, Inc. - Pipeline by Stage of Development, 2014
MediciNova, Inc. - Monotherapy Products in Pipeline, 2014
MediciNova, Inc. - Partnered Products in Pipeline, 2014
MediciNova, Inc. - Pipeline by Top 10 Target, 2014
MediciNova, Inc. - Pipeline by Top 10 Route of Administration, 2014
MediciNova, Inc. - Pipeline by Top 10 Molecule Type, 2014
MediciNova, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Skip to top


AnaptysBio, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 24 pages
EGEN, Inc. - Product Pipeline Review - 2014 US$ 1,125.00 Jul, 2014 · 24 pages
GenSpera, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 27 pages
ImmunoFrontier, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jun, 2015 · 22 pages
OncoImmune, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Aug, 2015 · 24 pages

Ask Your Question

MediciNova, Inc. - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: